When the COVID-19 pandemic hit the U.S. in March 2020, many drug developers were caught by surprise. With clinics overwhelmed by COVID patients and the reluctance of some patients to venture out to those clinics, many trials faced the prospect of being delayed or cancelled. Decentralized clinical trials (DCTs) and hybrid trials, which can take studies from the clinics and to the patients, seemed to be the solution to keep things on track.
But where do your sites stand on DCTs? Do they fully understand what they are and how they will impact the financial landscape? Are they a blessing or a curse to site personnel? Clinical Leader Live sat down with three site experts to discuss the pain points of DCTs, including costs, budgeting, training, support, staffing, resources, and more. As sites continue to struggle with the migration to DCTs, do your sites love or hate them, how do they feel about the sponsors they work with, and what can you do about it?